Drugs / DT-7012
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07213882 | Jan 2026 → Aug 2028 expected | Sezary syndrome, mycosis fungoides | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06819735 | Jun 2025 → Sep 2027 expected | cancer | Domain Therapeutics Australia Pty Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-30 | Domain Therapeutics SA | Results Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025 domaintherapeutics.com ↗
Preclinical data of DT-7012 position this Treg depleting anti-CCR8 antibody as a highly differentiated candidate for clinical development |
| 2025-04-01 | Domain Therapeutics SA | Results Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025 domaintherapeutics.com ↗
The study characterizes DT-7012’s binding properties, effector functions, and Treg-depleting activity, supporting its transition into clinical development. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-28 | Domain Therapeutics SA | Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors domaintherapeutics.com ↗ |
| 2025-04-30 | Domain Therapeutics SA | Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025 domaintherapeutics.com ↗ |
| 2025-04-01 | Domain Therapeutics SA | Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025 domaintherapeutics.com ↗ |
| 2024-06-06 | Domain Therapeutics SA | Domain Therapeutics strengthens its intellectual property for its series of Treg depleting anti-CCR8 antibodies, including best-in-class candidate DT-7012 domaintherapeutics.com ↗ |
| 2023-06-29 | Domain Therapeutics SA | Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening its unique portfolio of GPCR-targeting immunotherapies domaintherapeutics.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DT-7012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07213882 ↗ |
| Action | Deplete | “in vitro efficacy of their proprietary anti-CCR8 mAb DT7012 in the depletion of CTCL cells” NCT07213882 ↗ |
| Modality | Monoclonal antibody | “an anti-CCR8 monoclonal antibody” NCT06819735 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT06819735 ↗ |
| Target | CCR8 | “an anti-CCR8 monoclonal antibody” NCT06819735 ↗ |